We develop the idea of using data from the first 'few' patients entere
d in a clinical trial to estimate the final trial size needed to have
specified power for rejecting H-0 in favour of H-1 if a real differenc
e exists. When comparing means derived from Normally distributed data,
there is no important effect on test size, power or expected trial si
ze, provided that a minimum of about 20 degrees of freedom are used to
estimate residual variance. Relative advantages and disadvantages of
using larger internal pilot studies are presented. These revolve aroun
d crude expectations of the final study size, recruitment rate, durati
on of follow-up and practical constraints on the ability to prevent th
e circulation of unblinded randomization codes to investigators and th
ose involved in editing and checking data.